Trials / Terminated
TerminatedNCT00105313
Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
A Phase I Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507. For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and recovery of CD2 positive and total T-Cell populations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEDI-507 |
Timeline
- Start date
- 2005-02-01
- First posted
- 2005-03-14
- Last updated
- 2007-06-14
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00105313. Inclusion in this directory is not an endorsement.